HRMY:NASDAQ, Harmony Biosciences Holdings, Inc.
HRMY stock overview
Harmony Biosciences Holdings, Inc. (HRMY:NASDAQ) closed at $32.98 on November 19, 2026,
down 0.39% on the day.
The stock trades 24.2% below its 52-week high of $43.49
and 27.3% above its 52-week low of $25.90.
Over the past year, it lost 1.2%.
Harmony Biosciences Holdings, Inc. is part of the Health Care sector.
Key figures
- Price
- $32.98
- Day change
- -0.39%
- Volume
- 804,704
- Average volume
- 1,007,376
- Market cap
- 1B+
- 52-week range
- $25.90 – $43.49
- 50-day average
- $38.11
- 200-day average
- $34.51
Price action over the past year
In 252 trading sessions since November 19, 2025, HRMY closed higher on 129 days (51%).
Its best day was July 21, 2026 (+9.97%) and its worst was February 20, 2026 (-15.21%).
The stock moved 10% or more in a single session 1 time.
Recent signals
HRMY news
-
Nov 19, 2026:
Harmony Biosciences to Participate in Upcoming Investor Conferences
-
Nov 7, 2026:
Harmony Biosciences (HRMY) Stock May Be Undervalued On Earnings Power
-
Nov 5, 2026:
HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth
-
Nov 4, 2026:
Harmony Biosciences Holdings, Inc. Q3 2026 Earnings Call Summary
-
Nov 4, 2026:
Harmony Biosciences (HRMY) Q3 2026 Earnings Call Transcript
-
Nov 4, 2026:
Harmony Biosciences Misses As Royalty Costs Squeeze Margins And WAKIX Growth Cools, With February Patent Rulings Looming
-
Nov 4, 2026:
Harmony Biosciences Q3 Earnings Call Highlights
-
Nov 4, 2026:
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Lag Estimates
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs.
Similar stocks
Find more stocks like HRMY with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.